Coherus Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025
Coherus Oncology (Nasdaq: CHRS) has scheduled its second quarter 2025 financial results release for August 7, 2025, after market close. The company will host a conference call and webcast at 5:00 p.m. EDT on the same day to discuss the results and provide a business update.
Investors can access the conference call through toll-free (800-715-9871) or international (646-307-1963) dial-in numbers using Conference ID 8712736. A live webcast and archived replay will be available on the company's investor relations website.
Coherus Oncology (Nasdaq: CHRS) ha programmato la pubblicazione dei risultati finanziari del secondo trimestre 2025 per il 7 agosto 2025, dopo la chiusura del mercato. La societ脿 terr脿 una teleconferenza e una diretta web alle 17:00 EDT dello stesso giorno per discutere i risultati e fornire un aggiornamento aziendale.
Gli investitori potranno partecipare alla teleconferenza chiamando i numeri gratuiti (800-715-9871) o internazionali (646-307-1963) utilizzando l'ID conferenza 8712736. La diretta web e la registrazione saranno disponibili sul sito web delle relazioni con gli investitori della societ脿.
Coherus Oncology (Nasdaq: CHRS) ha programado la publicaci贸n de sus resultados financieros del segundo trimestre de 2025 para el 7 de agosto de 2025, despu茅s del cierre del mercado. La compa帽铆a realizar谩 una llamada de conferencia y una transmisi贸n en vivo a las 5:00 p.m. EDT del mismo d铆a para discutir los resultados y ofrecer una actualizaci贸n del negocio.
Los inversionistas pueden acceder a la llamada de conferencia mediante los n煤meros gratuitos (800-715-9871) o internacionales (646-307-1963) utilizando el ID de conferencia 8712736. La transmisi贸n en vivo y la repetici贸n archivada estar谩n disponibles en el sitio web de relaciones con inversionistas de la compa帽铆a.
Coherus Oncology (雮橃姢雼�: CHRS)電� 2025雲� 2攵勱赴 鞛鞁れ爜 氚滍憸毳� 2025雲� 8鞗� 7鞚� 鞛� 毵堦皭 頉勳棎 鞓堨爼頃橁碃 鞛堨姷雼堧嫟. 須岇偓電� 臧欖潃 雮� 霃欕秬 響滌鞁� 鞓ろ泟 5鞁�鞐� 鞁れ爜 氚滍憸 氚� 靷梾 順勴櫓 鞐呺嵃鞚错姼毳� 鞙勴暅 旎嵓霟办姢 旖滉臣 鞗轨簮鞀ろ姼毳� 歆勴枆頃� 鞓堨爼鞛呺媹雼�.
韴瀽鞛愲摛鞚� 氍措 鞝勴檾氩堩樃(800-715-9871) 霕愲姅 甑牅 鞝勴檾氩堩樃(646-307-1963)毳� 韱淀暣 旎嵓霟办姢 ID 8712736毳� 靷毄頃橃棳 旎嵓霟办姢 旖滌棎 彀胳棳頃� 靾� 鞛堨姷雼堧嫟. 鞁れ嫓臧� 鞗轨簮鞀ろ姼鞕� 雲鬼檾霅� 雼れ嫓氤搓赴電� 須岇偓鞚� 韴瀽鞛� 甏�瓿� 鞗轨偓鞚错姼鞐愳劀 鞝滉车霅╇媹雼�.
Coherus Oncology (Nasdaq : CHRS) a programm茅 la publication de ses r茅sultats financiers du deuxi猫me trimestre 2025 pour le 7 ao没t 2025, apr猫s la cl么ture du march茅. La soci茅t茅 organisera une conf茅rence t茅l茅phonique et une webdiffusion 脿 17h00 EDT le m锚me jour pour discuter des r茅sultats et fournir une mise 脿 jour commerciale.
Les investisseurs peuvent acc茅der 脿 la conf茅rence t茅l茅phonique via les num茅ros gratuits (800-715-9871) ou internationaux (646-307-1963) en utilisant l'identifiant de conf茅rence 8712736. Une webdiffusion en direct et un replay archiv茅s seront disponibles sur le site des relations investisseurs de la soci茅t茅.
Coherus Oncology (Nasdaq: CHRS) hat die Ver枚ffentlichung der Finanzergebnisse f眉r das zweite Quartal 2025 f眉r den 7. August 2025, nach B枚rsenschluss, geplant. Das Unternehmen wird am selben Tag um 17:00 Uhr EDT eine Telefonkonferenz und einen Webcast abhalten, um die Ergebnisse zu besprechen und ein Gesch盲ftsupdate zu geben.
Investoren k枚nnen 眉ber geb眉hrenfreie Nummern (800-715-9871) oder internationale Nummern (646-307-1963) mit der Konferenz-ID 8712736 an der Telefonkonferenz teilnehmen. Ein Live-Webcast sowie eine Archiv-Wiedergabe werden auf der Investor-Relations-Website des Unternehmens verf眉gbar sein.
- None.
- None.
REDWOOD CITY, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc.聽(Coherus, Coherus Oncology or the Company, Nasdaq: CHRS), today announced that its second quarter 2025 financial results will be released after market close on Thursday, August 7, 2025. Starting at 5:00 p.m. EDT on August 7, 2025, Coherus鈥� management team will host a conference call and webcast to discuss financial results and provide a general business update.
A webcast replay will be available on https://investors.coherus.com following the conclusion of the live conference call.
Conference Call Information
When: Thursday, August 7, 2025, starting at 5:00 p.m. Eastern Daylight Time
To access the conference call:
- TOLL-FREE DIAL-IN: (800) 715-9871
- INTERNATIONAL DIAL-IN: (646) 307-1963
- Conference ID 8712736
Webcast: https://edge.media-server.com/mmc/p/skv7e6d2
The press release with the second quarter 2025 financial results and related materials will be available at https://investors.coherus.com before the start of the conference call.
A live and archived webcast will be available on the 鈥淚nvestors鈥� section of the Coherus website at https://investors.coherus.com/events-presentations.
Please dial in 15 minutes early to ensure a timely connection to the call.
Disclosure Information
Coherus uses the 鈥痺ebsite as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.鈥�
About Coherus Oncology
Coherus Oncology is a fully integrated commercial-stage innovative oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI庐 (toripalimab-tpzi), growing revenues and a promising pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Our strategy is to grow sales of LOQTORZI in nasopharyngeal carcinoma and advance the development of new indications for LOQTORZI in combination with both our pipeline candidates as well as our partners鈥�, driving sales multiples and synergies from proprietary combinations.
Coherus鈥� innovative oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor response and enhance outcomes for patients with cancer. CHS-114 is a highly selective cytolytic anti-CCR8 antibody currently in Phase 1b studies in patients with advanced solid tumors, including head and neck squamous cell carcinoma, gastric cancer, and esophageal cancer. Casdozokitug is a novel IL-27 antagonistic antibody currently being evaluated in multiple Phase 1/2 and Phase 2 studies in patients with advanced solid tumors, including non-small cell lung cancer and hepatocellular carcinoma.
For more information about LOQTORZI, including the U.S. Prescribing Information and important safety information, please visit .
Coherus Contact Information
Investors:
Jodi Sievers
VP, Investor Relations & Corporate Communications
[email protected]
FAQ
When will Coherus Oncology (CHRS) report Q2 2025 earnings?
How can investors access Coherus Oncology's Q2 2025 earnings call?
Where can I find Coherus Oncology's Q2 2025 earnings materials?
Will there be a replay of Coherus Oncology's Q2 2025 earnings call?
